CUVL (CUVL) FinancialsCUVLCUVL

Evaluating the bottom line, Clinuvel Pharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.11%, provide a clear picture of how effectively CUVL converts its operational activities into shareholder value.

In the context of the broader market, CUVL competes directly with industry leaders such as AVIR and ARCT. With a market capitalization of $316.69M, it holds a significant position in the sector. When comparing efficiency, CUVL's gross margin of N/A stands against AVIR's N/A and ARCT's 100.00%. Such benchmarking helps identify whether Clinuvel Pharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

Clinuvel reported a net profit of AUD 33.9 million for FY2026, marking its tenth consecutive year of profitability, but this is a decline from the previous year.